EANS-News: Agennix AG Schedules Fiscal Year 2012 Reporting Date and Conference
Call on March 28
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
annual report
Planegg/Munich (Germany) and Princeton, NJ, February 19, 2013 (euro adhoc) -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will
publish its financial results for fiscal year 2012 on Thursday, March 28, 2013
followed by a conference call to discuss the results and to provide a business
update.
The conference call, which will be conducted in English, will be also held on
Thursday, March 28, 2013 at 9 AM ET/2 PM CET.
A live webcast will be available on the Agennix website at www.agennix.com. A
replay will be available via the website following the live event.
Dial-in numbers for the call are as follows:
Participants from Europe: 0049 (0)69 710 445 598
0044 (0)20 3003 2666
Participants from the U.S.: 1 212 999 6659
Please dial in 10 minutes before the beginning of the call.
About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially lengthen
and improve the lives of critically ill patients in areas of major unmet medical
need. The Company's clinical development programs include oral talactoferrin
alfa; a topical gel form of talactoferrin and RGB-286638, a multi-targeted
kinase inhibitor. Agennix's registered seat is in Heidelberg, Germany. The
Company has two sites of operation: Planegg/Munich, Germany and Princeton, New
Jersey. For additional information, please visit the Agennix website at
www.agennix.com.
This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from those
expressed or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution investors not
to place undue reliance on the forward-looking statements contained in this
press release. The achievement of positive results in early stage clinical
studies does not ensure that later stage clinical studies will be successful.
There can be no guarantee that the Company will have or be able to obtain the
financial resources to conduct additional studies with its product candidates or
that it will be successful in pursuing a strategic transaction. Forward-looking
statements speak only as of the date on which they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.
Agennix® is a trademark of Agennix AG.
Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com
In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
regulated dealing/prime standard: Frankfurt
language: English